368 related articles for article (PubMed ID: 32796758)
1. Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors.
Vilariño N; Bruna J; Kalofonou F; Anastopoulou GG; Argyriou AA
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32796758
[TBL] [Abstract][Full Text] [Related]
2. Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice.
Berzero G; Picca A; Psimaras D
Curr Opin Oncol; 2020 Nov; 32(6):603-612. PubMed ID: 32852312
[TBL] [Abstract][Full Text] [Related]
3. Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials.
Bruna J; Argyriou AA; Anastopoulou GG; Alemany M; Nadal E; Kalofonou F; Piulats JM; Simó M; Velasco R; Kalofonos HP
J Peripher Nerv Syst; 2020 Jun; 25(2):171-177. PubMed ID: 32166812
[TBL] [Abstract][Full Text] [Related]
4. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management.
Farina A; Villagrán-García M; Honnorat J
Rev Neurol (Paris); 2023 Jun; 179(5):506-515. PubMed ID: 36934022
[TBL] [Abstract][Full Text] [Related]
5. Neurologic manifestations of autoimmunity with immune checkpoint inhibitors.
McCombe JA; Sechi E; Zekeridou A
Handb Clin Neurol; 2024; 200():449-465. PubMed ID: 38494296
[TBL] [Abstract][Full Text] [Related]
6. [Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies].
Tang H; Guan M; Sun Z; Bai CM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Dec; 42(6):825-830. PubMed ID: 33423733
[TBL] [Abstract][Full Text] [Related]
7. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
8. [Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis].
Liu Y; Chen Y; Zeng Z; Liu A
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):668-672. PubMed ID: 34521189
[TBL] [Abstract][Full Text] [Related]
9. Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature.
Fan S; Ren H; Zhao L; Yin J; Feng G; Wang J; Guan H
Asia Pac J Clin Oncol; 2020 Dec; 16(6):291-298. PubMed ID: 32893999
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors and vasculitis.
Boland P; Heath J; Sandigursky S
Curr Opin Rheumatol; 2020 Jan; 32(1):53-56. PubMed ID: 31599800
[TBL] [Abstract][Full Text] [Related]
11. Neurological toxicities associated with immune-checkpoint inhibitors.
Touat M; Talmasov D; Ricard D; Psimaras D
Curr Opin Neurol; 2017 Dec; 30(6):659-668. PubMed ID: 28938341
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors and Neurotoxicity.
Zhao Z; Zhang C; Zhou L; Dong P; Shi L
Curr Neuropharmacol; 2021; 19(8):1246-1263. PubMed ID: 33380303
[TBL] [Abstract][Full Text] [Related]
13. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity.
Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L
Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171
[TBL] [Abstract][Full Text] [Related]
14. Central nervous system injury from novel cancer immunotherapies.
Winter SF; Vaios EJ; Dietrich J
Curr Opin Neurol; 2020 Dec; 33(6):723-735. PubMed ID: 32941192
[TBL] [Abstract][Full Text] [Related]
15. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors.
Graus F; Dalmau J
Nat Rev Clin Oncol; 2019 Sep; 16(9):535-548. PubMed ID: 30867573
[TBL] [Abstract][Full Text] [Related]
16. Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction.
Duan L; Wang L; Wang H; Si X; Zhang L; Liu X; Li Y; Guo X; Zhou J; Zhu H; Zhang L
Thorac Cancer; 2020 Apr; 11(4):1099-1104. PubMed ID: 32043816
[TBL] [Abstract][Full Text] [Related]
17. Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review.
Spagnolo F; Boutros A; Croce E; Cecchi F; Arecco L; Tanda E; Pronzato P; Lambertini M
Eur J Clin Invest; 2021 Jul; 51(7):e13604. PubMed ID: 34021591
[TBL] [Abstract][Full Text] [Related]
18. Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management.
Ruggiero R; Di Napoli R; Balzano N; Ruggiero D; Riccardi C; Anatriello A; Cantone A; Sportiello L; Rossi F; Capuano A
Expert Rev Clin Pharmacol; 2023 May; 16(5):423-434. PubMed ID: 37144360
[TBL] [Abstract][Full Text] [Related]
19. Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach.
de La Rochefoucauld J; Noël N; Lambotte O
Intern Emerg Med; 2020 Jun; 15(4):587-598. PubMed ID: 32144552
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors.
Lee DJ; Lee HJ; Farmer JR; Reynolds KL
Curr Cardiol Rep; 2021 Jul; 23(8):98. PubMed ID: 34196833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
